The administrative Core is essential for providing overall guidance and oversight to the Wellstone Center. The Core will be directed by Jeffrey S. Chamberlain, Ph.D. with assistance from Stephen Tapscott, M.D./Ph.D. Day to day operation ofthe Core will be handled by Ms. Roberta Miller, who has extensive experience in overseeing Center and Program Project grants.
The specific aims of the Administrative Core are as follows: 1. To integrate and manage the activities and interactions of the Projects and Cores through regular meetings, correspondence and by developing and maintaining a center website. 2. To review and report utilization of funds of all projects, cores, and resources, and to contribute to the coordination of effort to refine and standardize operational procedures within the center. 3. To provide oversight support and advice for the Director and Co-director by monitoring and reporting the activities of the center and to aid in the creation, approval, and support of a Center Advisory Committee (CAC) and local executive committee. 4. To support interaction and collaboration with the scientific and lay communities to develop relevant goals for the MDCRC within the center, as well as the NIH Science office to develop mutual MDCRC goals for research activity between Centers. The Core will also encourage collaboration and interests of scientists inside and outside the institutional community. 5. To promote and oversee the use of the core facilities, exchange of information and training and techniques among researchers within the UW and other institutions as well as patients using multiple mechanisms such as brochures, websites, and seminars.

Public Health Relevance

The Administrative Core is important for providing oversight of the Center; projects and Cores. It will be supported by the P.I.; the Center co-director; an executive Committee of senior scientists affiliated with the project; and an external Center Advisory Committee.

National Institute of Health (NIH)
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Specialized Center--Cooperative Agreements (U54)
Project #
Application #
Study Section
Special Emphasis Panel (ZAR1-KM (M1))
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Washington
United States
Zip Code
Bengtsson, Niclas E; Hall, John K; Odom, Guy L et al. (2017) Muscle-specific CRISPR/Cas9 dystrophin gene editing ameliorates pathophysiology in a mouse model for Duchenne muscular dystrophy. Nat Commun 8:14454
Mack, David L; Poulard, Karine; Goddard, Melissa A et al. (2017) Systemic AAV8-Mediated Gene Therapy Drives Whole-Body Correction of Myotubular Myopathy in Dogs. Mol Ther 25:839-854
Chamberlain, Joel R; Chamberlain, Jeffrey S (2017) Progress toward Gene Therapy for Duchenne Muscular Dystrophy. Mol Ther 25:1125-1131
Amoasii, Leonela; Long, Chengzu; Li, Hui et al. (2017) Single-cut genome editing restores dystrophin expression in a new mouse model of muscular dystrophy. Sci Transl Med 9:
Elverman, Matthew; Goddard, Melissa A; Mack, David et al. (2017) Long-term effects of systemic gene therapy in a canine model of myotubular myopathy. Muscle Nerve 56:943-953
Whitehead, Nicholas P; Bible, Kenneth L; Kim, Min Jeong et al. (2016) Validation of ultrasonography for non-invasive assessment of diaphragm function in muscular dystrophy. J Physiol 594:7215-7227
Kolwicz Jr, Stephen C; Odom, Guy L; Nowakowski, Sarah G et al. (2016) AAV6-mediated Cardiac-specific Overexpression of Ribonucleotide Reductase Enhances Myocardial Contractility. Mol Ther 24:240-250
Lawlor, Michael W; Beggs, Alan H; Buj-Bello, Ana et al. (2016) Skeletal Muscle Pathology in X-Linked Myotubular Myopathy: Review With Cross-Species Comparisons. J Neuropathol Exp Neurol 75:102-10
Bengtsson, Niclas E; Seto, Jane T; Hall, John K et al. (2016) Progress and prospects of gene therapy clinical trials for the muscular dystrophies. Hum Mol Genet 25:R9-17
Davey, Jonathan R; Watt, Kevin I; Parker, Benjamin L et al. (2016) Integrated expression analysis of muscle hypertrophy identifies Asb2 as a negative regulator of muscle mass. JCI Insight 1:

Showing the most recent 10 out of 19 publications